@B&BB... What's it to you? I actually don't follow this much anymore, because there isn't much to follow. But they announced an IPO, and spent a lot of money doing everything needed to re-enter equity markets. So it seems childish -- and, frankly, stupid -- to assume they did all that as some sort of deception. It's very obvious that their third-rate investment bank has failed to generate the interest required to price the IPO -- difficult these days in mainstream biotech, let alone this. So now, presumably, they have hired a consultant to work on that. Do I care? Not really. Do I expect it to succeed? No. Do I still glance at their SEC filings and report what I see? Sure. Why not? I own a lot of stock. Do I expect it to amount to anything? No.
